Adverum Biotechnologies

Adverum Biotechnologies

Adverum is a gene therapy company committed to discovering and developing novel medicines to patients living with rare diseases and diseases of the eye.

Adverum, formerly Avalanche Biotechnologies, is a biotechnology company developing gene therapies for patients living with rare diseases and diseases of the eye that is headquartered in Menlo Park, California and was founded in 2006 by Mark S. Blumenkranz, Mitchell H. Finer, Steven D. Schwartz, and Thomas W. Chalberg. The company officially became Adverum Biotechnologies in May, 2016 after the merger of Avalanche Biotechnologies and Annapurna Therapeutics.

Funding

Venture round I

On November 22, 2013 Adverum Biotechnologies completed a venture capital round raising $5.7 million in capital from undisclosed investors.

Series B

On April 22, 2014 Adverum Biotechnologies completed their series B funding round with $55 million in capital from Venrock (lead investor), Sabby Capital, Rock Springs Capital, Redmile Group, Deerfield, and Adage Capital management.

Venture round II

On September 7, 2014 Adverum Biotechnologies completed their second venture capital round with $10 million in funding from undisclosed investors.

Timeline

May 7, 2016

Merger of Avalanche Biotechnologies and Annapurna Therapeutics

The company officially became Adverum Biotechnologies in May, 2016 after the merger of Avalanche Biotechnologies and Annapurna Therapeutics.

September 19, 2014

Venture funding round II

On September 7, 2014 Adverum Biotechnologies completed their second venture capital round with $10 million in funding from undisclosed investors.

April 22, 2014

Series B funding round

On April 22, 2014 Adverum Biotechnologies completed their series B funding round with $55 million in capital from Venrock (lead investor), Sabby Capital, Rock Springs Capital, Redmile Group, Deerfield, and Adage Capital management.

November 2, 2013

Venture funding round I

On November 22, 2013 Adverum Biotechnologies completed a venture capital round raising $5.7 million in capital from undisclosed investor

People

Name
Role
LinkedIn

Mark S. Blumenkranz

Co-Founder

Carla Fiankan

Vice President, Regulatory Affairs

Claire Gelfman

Executive Director, Pharmaceutical Development

Jennifer Cheng

Vice President and General Council

Leone Patterson

CEO, Director, and CFO

Mehdi Gasmi

President and CSO

Michael Steel

Vice President, Quality

Mike Fitzgerald

Vice President , Human Resources

Mitchell H. Finer

Co-Founder

Pratik Jaluria

Executive Director, Process Development and Manufacturing

Steven D. Schwartz

Co-Founder

Thomas W. Chalberg

Co-Founder

Further reading

Title
Author
Link
Type
Date

Here's Why Adverum Biotechnologies Dropped as Much as 42.4% Today

Maxx Chatsko

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.